DA Davidson Has Pessimistic Outlook of USNA FY2024 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at DA Davidson dropped their FY2024 EPS estimates for shares of USANA Health Sciences in a research note issued on Wednesday, October 23rd. DA Davidson analyst L. Weiser now forecasts that the company will post earnings per share of $2.45 for the year, down from their prior estimate of $2.51. DA Davidson has a “Neutral” rating and a $35.00 price target on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. DA Davidson also issued estimates for USANA Health Sciences’ FY2025 earnings at $2.23 EPS.

Separately, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Stock Performance

NYSE USNA opened at $36.81 on Thursday. USANA Health Sciences has a one year low of $34.15 and a one year high of $54.81. The business has a fifty day moving average price of $37.90 and a 200 day moving average price of $42.44. The company has a market cap of $701.27 million, a P/E ratio of 11.47, a P/E/G ratio of 1.15 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. During the same quarter last year, the business posted $0.59 earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC increased its position in shares of USANA Health Sciences by 4.4% during the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after acquiring an additional 322 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares during the period. Public Sector Pension Investment Board increased its holdings in USANA Health Sciences by 5.4% in the 2nd quarter. Public Sector Pension Investment Board now owns 24,270 shares of the company’s stock valued at $1,098,000 after purchasing an additional 1,242 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in USANA Health Sciences by 22.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after purchasing an additional 1,560 shares during the period. Finally, BOKF NA lifted its stake in USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after purchasing an additional 2,031 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock valued at $311,670 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.